Compare Stocks: ZNTL, TBPH, ARDX, and GYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.48 -3.9%	$4.17	$3.33 ▼ $8.40	$902.06M	0.7	3.88 million shs	6.28 million shs
GYRE Gyre Therapeutics	$7.40 -1.2%	$6.57	$5.44 ▼ $9.42	$835.21M	1.92	156,271 shs	164,517 shs
TBPH Theravance Biopharma	$17.03	$16.97	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	10.02 million shs
ZNTL Zentalis Pharmaceuticals	$2.87 -6.8%	$4.03	$1.21 ▼ $6.95	$220.75M	1.85	830,667 shs	1.45 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-3.87%	+2.65%	-6.95%	-42.57%	-43.41%
GYRE Gyre Therapeutics	-1.20%	+10.45%	+14.91%	+18.78%	+1.37%
TBPH Theravance Biopharma	0.00%	0.00%	+0.12%	-2.07%	+21.04%
ZNTL Zentalis Pharmaceuticals	-6.82%	-7.42%	-23.67%	-24.27%	+91.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.48 -3.9%	$4.17	$3.33 ▼ $8.40	$902.06M	0.7	3.88 million shs	6.28 million shs
GYRE Gyre Therapeutics	$7.40 -1.2%	$6.57	$5.44 ▼ $9.42	$835.21M	1.92	156,271 shs	164,517 shs
TBPH Theravance Biopharma	$17.03	$16.97	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	10.02 million shs
ZNTL Zentalis Pharmaceuticals	$2.87 -6.8%	$4.03	$1.21 ▼ $6.95	$220.75M	1.85	830,667 shs	1.45 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-3.87%	+2.65%	-6.95%	-42.57%	-43.41%
GYRE Gyre Therapeutics	-1.20%	+10.45%	+14.91%	+18.78%	+1.37%
TBPH Theravance Biopharma	0.00%	0.00%	+0.12%	-2.07%	+21.04%
ZNTL Zentalis Pharmaceuticals	-6.82%	-7.42%	-23.67%	-24.27%	+91.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.75	Moderate Buy	$13.90	299.43% Upside
GYRE Gyre Therapeutics	1.67	Reduce	$16.00	116.22% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	13.92% Upside
ZNTL Zentalis Pharmaceuticals	2.40	Hold	$6.75	135.19% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, TBPH, ARDX, and GYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/18/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/17/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00
8/7/2026	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/7/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $14.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	2.13	N/A	N/A	$0.69 per share	5.04
GYRE Gyre Therapeutics	$116.59M	7.08	$0.22 per share	33.71	$1.48 per share	5.00
TBPH Theravance Biopharma	$107.46M	8.23	N/A	N/A	$5.86 per share	2.91
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	$2.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	14.50	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
GYRE Gyre Therapeutics	$5.03M	-$0.21	N/A	N/A	N/A	-15.47%	-6.57%	-5.35%	11/6/2026 (Estimated)
TBPH Theravance Biopharma	$105.89M	$1.01	16.86	21.02	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest ZNTL, TBPH, ARDX, and GYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/7/2026	Q2 2026	GYRE Gyre Therapeutics	-$0.0567	-$0.12	-$0.0633	-$0.12	$26.49 million	$29.11 million
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
GYRE Gyre Therapeutics	N/A	4.26	3.86
TBPH Theravance Biopharma	N/A	13.54	13.54
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
GYRE Gyre Therapeutics	23.99%
TBPH Theravance Biopharma	99.10%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
GYRE Gyre Therapeutics	9.50%
TBPH Theravance Biopharma	7.65%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	489	249.19 million	235.98 million	Optionable
GYRE Gyre Therapeutics	618	111.51 million	100.92 million	No Data
TBPH Theravance Biopharma	90	51.92 million	47.95 million	Optionable
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable

ZNTL, TBPH, ARDX, and GYRE Headlines

Recent News About These Companies

Financial Contrast: Harmony Biosciences (NASDAQ:HRMY) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 22 at 6:16 AM | americanbankingnews.com

Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs

September 18, 2026 | ad-hoc-news.deA

William Blair Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 16, 2026 | marketbeat.com

Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Sol-Gel Technologies (NASDAQ:SLGL)

September 16, 2026 | americanbankingnews.com

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

September 16, 2026 | streetinsider.com

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts

September 10, 2026 | marketbeat.com

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

September 4, 2026 | marketbeat.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2, 2026 | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

August 31, 2026 | seekingalpha.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

August 29, 2026 | marketbeat.com

Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 27, 2026 | marketbeat.com

652,750 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

3,947,913 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, TBPH, ARDX, and GYRE Company Descriptions

Ardelyx NASDAQ:ARDX

$3.48 -0.14 (-3.87%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.45 -0.03 (-0.92%)

As of 07:31 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Gyre Therapeutics NASDAQ:GYRE

$7.40 -0.09 (-1.20%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$7.38 -0.03 (-0.34%)

As of 05:10 AM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Theravance Biopharma NASDAQ:TBPH

$17.03 0.00 (0.00%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$17.05 +0.02 (+0.09%)

As of 09/23/2026 07:30 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$2.87 -0.21 (-6.82%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.04 (-1.22%)

As of 05:07 AM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZNTL, TBPH, ARDX, and GYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZNTL, TBPH, ARDX, and GYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZNTL, TBPH, ARDX, and GYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, TBPH, ARDX, and GYRE Company Descriptions

Ardelyx NASDAQ:ARDX

Gyre Therapeutics NASDAQ:GYRE

Theravance Biopharma NASDAQ:TBPH

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZNTL, TBPH, ARDX, and GYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZNTL, TBPH, ARDX, and GYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZNTL, TBPH, ARDX, and GYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, TBPH, ARDX, and GYRE Company Descriptions

Ardelyx NASDAQ:ARDX

Gyre Therapeutics NASDAQ:GYRE

Theravance Biopharma NASDAQ:TBPH

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools